DarioHealth Corp. operates as a digital therapeutics company in the United States, Canada, the European Union, Australia, and New Zealand. The company offers Dario Tools, which are devices that integrate with applications on a user's smartphone; DarioEngage, a population health management platform; and the Dario Loop, an AI-driven journey engine. It also sells device-specific disposables test strip cartridges, lancets, and Dario Blood Glucose Monitoring System; and Dario Smart Diabetes Management Solution, which includes tools to help diabetic patients manage their disease. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was founded in 2011 and is based in New York, New York.
IPO Year:
Exchange: NASDAQ
Website: mydario.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/13/2022 | $8.75 | Neutral → Buy | Alliance Global Partners |
| 1/26/2022 | $28.00 → $25.00 | Buy | Aegis Capital |
| 8/19/2021 | $35.00 → $28.00 | Buy | Aegis Capital |
Concurrently, the Company accepted the resignations of Dr. Colin Goddard and Mr. Joacim Borg OS Therapies (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate biopharmaceutical company, today announced the appointments of Avril McKean Dieser, MA, JD and Olivier R. Jarry, MS, MBA as independent members of the Company's Board of Directors. Collectively, Ms. McKean Dieser and Mr. Jarry bring over 50 years of biopharmaceutical executive decision-making experience to the Company, with a specific focus in commercializing biologic products. "OS Therapies is thrilled to welcome Ms. McKean Dieser and Mr. Jarry to our Board of Directors," sa
After two decades of successfully scaling multiple healthcare companies, Steven Nelson joins DarioHealth as Chief Commercial Officer to accelerate revenue growth across the health plans, employers and pharma channels NEW YORK, June 5, 2024 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario", "DarioHealth" or the "Company"), a leader in the global digital health market, announced today a strategic reorganization designed to streamline leadership and focus the organization on accelerating its commercialization efforts. This move reflects the Company's commitment to bringing its innovative solutions to the market faster, maximizing customer impact, and driving the organization to profitabi
Dario also appoints digital veteran, Arnaud Robert, to the role of Strategic Advisor to the Chief Executive Officer The appointments strengthen Dario's ability to scale its digital therapeutics platform to meet growing market demand NEW YORK, April 4, 2023 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) (the "Company" or "Dario"), a leader in the global digital therapeutics (DTx) market, announced today that digital health veteran, Eitan Shay, is joining the Company in the newly created position of Chief Product Officer. Mr. Shay previously held product leadership roles at digital health companies Livongo and Teladoc Health as well as senior leadership roles at Meta Platforms. Dario also
Mr. Kaplan brings a wealth of experience in business strategy specifically in healthcare and digital health NEW YORK, Feb. 23, 2023 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) (the "Company"), a leader in the global digital therapeutics (DTx) market, announced today the appointment of Jon Kaplan to serve as a board member effective immediately. Mr. Kaplan is a Managing Director and Senior Partner at Boston Consulting Group (BCG), serving as a core member of the strategy and health care practices and leading BCG's transformation initiative for the future evolution of healthcare in the United States and its impact globally. He has previously served in advisory board roles at digital health
NEW YORK, Nov. 15, 2021 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO), a pioneer in the global digital therapeutics market, today announced that the Company appointed Jerrod Helms to the newly created role of Chief Commercial Officer (CCO) to support the rapid expansion of business in the employer, payer, provider and partnership markets that the company has seen over the last quarter and the anticipated acceleration into 2022. Mr. Helms will report to Rick Anderson, President and General Manager North America. "Dario is experiencing significant commercial acceleration as demonstrated by the number of recent customer wins and the expanding opportunity going forward as demand for our multi-
NEW YORK, Jan. 21, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics (DTx) market, announced today the appointment of Chris Chan as Senior Vice President of Employer Sales. Mr. Chan will be responsible for leading growth initiatives in the self-insured employer market. Mr. Chan brings a unique perspective and strong understanding of the self-insured employer marketplace for digital health and DTx solutions. Mr. Chan was most recently Chief Marketing Officer at SleepQuest; a sleep apnea focused technology and telehealth company. Prior to that role, Mr. Chan was a founding member, team leader, and innovation imaginer at Mercer LABS, where he
NEW YORK, January 7, 2021 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, announced today the appointment of Claudia Rimerman Kraut as Vice President of Broker and Consultant Partnerships. In the newly created role, Ms. Kraut will be a senior member of the employer sales team and lead Dario's benefit consultant and alliance outreach as part of the self-insured employers and managed care sales organization. Ms. Kraut brings a strong combination of benefits, partnerships, and digital health experience, most recently as Director of Alliances at Omada Health, where she successfully grew alliances with benefits consultants and other partne
SCHEDULE 13G/A - DarioHealth Corp. (0001533998) (Subject)
10-Q - DarioHealth Corp. (0001533998) (Filer)
DEF 14A - DarioHealth Corp. (0001533998) (Filer)
8-K - DarioHealth Corp. (0001533998) (Filer)
8-K - DarioHealth Corp. (0001533998) (Filer)
10-Q - DarioHealth Corp. (0001533998) (Filer)
S-8 - DarioHealth Corp. (0001533998) (Filer)
8-K - DarioHealth Corp. (0001533998) (Filer)
8-K - DarioHealth Corp. (0001533998) (Filer)
8-K - DarioHealth Corp. (0001533998) (Filer)
4 - DarioHealth Corp. (0001533998) (Issuer)
4 - DarioHealth Corp. (0001533998) (Issuer)
4 - DarioHealth Corp. (0001533998) (Issuer)
4 - DarioHealth Corp. (0001533998) (Issuer)
4 - DarioHealth Corp. (0001533998) (Issuer)
4 - DarioHealth Corp. (0001533998) (Issuer)
4 - DarioHealth Corp. (0001533998) (Issuer)
4 - DarioHealth Corp. (0001533998) (Issuer)
4 - DarioHealth Corp. (0001533998) (Issuer)
3 - DarioHealth Corp. (0001533998) (Issuer)
Demonstrated strong improvements in financial performance and business momentum.Q3 revenue of $7.42 million increased 18.7% over Q2 2024 and 111% compared to Q3 2023, driven by expansion of B2B2C revenues.Q3 operating loss decreased sequentially by 25.7% to $12 million on a GAAP basis and by 33.3% to $7.1 million on a non-GAAP basis over Q2 2024.Executed synergies from the Dario-Twill merger, expected to reduce operating expenses by approximately 38% by Q1 2025 (compared to Q1 2024) and contributing to an expected 49% reduction in operating losses by Q1 2025 and 59% in non-GAAP operating losses.Significant wins include: 10 B2B2C clients, including a national Medicare advantage health plan, a
Company to host conference call and webcast at 8:30am ET NEW YORK, Oct. 23, 2024 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a global leader in digital health, announced today that it will release its financial results for the 3rd quarter ended September 30th, 2024 and will host a conference call and webcast at 8:30 am Eastern Time, on Thursday, November 7th, 2024, before the market opens. Erez Raphael, Chief Executive Officer, and Steven Nelson, Chief Commercial Officer, will host the call. Conference Call Details Date: Thursday, November 7th, 8:30am ET Dial-in Number: 1-800-717-1738 (domestic) or 1-646-307-1865 (international) Call me™: https://emportal
Q2 revenue of $6.26 million reflects an increase of 8.6% over Q1 2024, and an increase of 1.7% over Q2 of 2023, driven primarily by increased B2B2C revenues Q2 commercial and consumer revenues totaled $7.34 million before a non-recurring price concession in collaboration with a pharma partner, compared to $3.57 million for Q2 of 2023, representing a 105% increaseCore B2B2C revenue channel, recurring revenues from employers and health plans in the second quarter totaled $5.5 million, an increase of 315% year over year and 60% sequentially from the first quarter of 2024Made progress on collaboration with existing and potential pharma clients to accelerate a transformation to a new, recurring,
Company to host conference call and webcast at 8:30am ET NEW YORK, July 30, 2024 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO), a leader in the global digital therapeutics (DTx) market, announced today that it will release its financial results for the 2nd quarter ended June 30th, 2024, on Thursday, August 8th, 2024, before the market opens and will host a conference call and webcast at 8:30 am Eastern Time. Erez Raphael, Chief Executive Officer, and Steven Nelson, Chief Commercial Officer, will host the call. Conference Call Details Date: Thursday, August 8th, 8:30am ET Dial-in Number: 1-800-717-1738 (domestic) or 1-646-307-1865 (international) Call me™: https://emportal.ink/3V5ogDP Part
First quarter revenue of $5.8 million reflects an increase of 59% over fourth quarter of 2023 primarily resulting from an increase in B2B2C revenues and reflects a decrease of 18.5% compared to the first quarter of 2023 due to milestone driven revenues.Core revenue channel B2B2C, employers and health plans recurring revenues in the first quarter totaled $3.47 million, an increase of 176% year over year and 210% sequentially from $1.12 million in the fourth quarter 2023 as the core business continues to gain traction, as well as the addition of Twill Inc. revenues post February 15th closingLaunched the Aetna platform generating revenue in Q1 2024 as Aetna continues to add employers to the pla
Company to host conference call and webcast at 8:30am ET NEW YORK, May 7, 2024 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO), a leader in the global digital therapeutics (DTx) market, announced today that it will release its financial results for the 1st quarter ended March 31st, 2024, on Wednesday, May 15th, 2024, before the market opens and will host a conference call and webcast at 8:30 am Eastern Time. Erez Raphael, Chief Executive Officer and Rick Anderson, President, will host the call. Conference Call Details Date: Wednesday, May 15th, 8:30am ET Dial-in Number: 1-888-886-7786 (domestic) or 1-416-764-8658 (international) Call me™: https://emportal.ink/3VOj7AC Participants can use t
Full-year 2023 revenue of $20.4 million reflects a decrease from 2022 revenue of $7.3 due to a managed decrease in B2C and strategic milestone revenue as the core B2B2C revenue increased.2023 B2B2C, employers and health plans recurring revenues increased 39% year over year as the core business continues to gain traction.Commercial revenues in 2023 generated majority of the revenue with B2B2C growing from 13% to 25% of total revenue from 2022 to 2023.GAAP operating expenses decreased by 11.2% sequentially from the third quarter of 2023.Non-GAAP operating expenses decreased 9.4% sequentially from the third quarter to $9.9M. Signed multiple customers onto the Aetna platform which subsequently l
Company to host conference call and webcast at 8:30am ET NEW YORK, March 21, 2024 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO), a leader in the global digital therapeutics (DTx) market, announced today that it will release its financial results for the 4th quarter ended December 31, 2023, on Thursday, March 28th, 2024, before the market opens and will host a conference call and webcast at 8:30 am Eastern Time. Erez Raphael, Chief Executive Officer and Rick Anderson, President, will host the call. Conference Call Details Date: Thursday, March 28th, 8:30am ET Dial-in Number: 1-888-886-7786 (domestic) or 1-416-764-8658 (international) Call me™: https://emportal.ink/3T9QM65 Participants can
Expecting nearly doubling Dario's pro forma revenues in 2023 Acquisition is immediately accretive to revenue and gross margins and expected to accelerate path to profitability Concurrent with the acquisition Dario prices $22.4 million equity financing Company to host conference call today at 8:30am ET. Dial-in and replay information below NEW YORK, Feb. 21, 2024 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company") announced today that it has acquired Twill, Inc. ("Twill"), a leader in digital-led care. The combination enables Dario to create one of the most comprehensive digital offerings in the market for chronic conditions, spanning a wide spectrum of health and well-
- Generated sequential B2B recurring revenue growth for the tenth consecutive quarter - Revenues of $6.15 million (pre-announced), compared to $6.18 million in the second quarter of 2022, a 0.5% decrease resulting from a delay with one of our strategic partners - Improved gross profit margin to 33.7% of revenues for the second quarter of 2023, up from 18.4% for the second quarter of 2022 - Improved proforma gross profit margin to 51.5% of revenues for the second quarter of 2023, up from 36.1% for the second quarter of 2022· - Reduced operating expenses by 13% in the second quarter of 2023, as compared to the second quarter of 2022 - Launched hypertension solution with a large regional healt
4 - DarioHealth Corp. (0001533998) (Issuer)
4 - DarioHealth Corp. (0001533998) (Issuer)
4 - DarioHealth Corp. (0001533998) (Issuer)
4 - DarioHealth Corp. (0001533998) (Issuer)
4 - DarioHealth Corp. (0001533998) (Issuer)
4 - DarioHealth Corp. (0001533998) (Issuer)
4 - DarioHealth Corp. (0001533998) (Issuer)
4 - DarioHealth Corp. (0001533998) (Issuer)
Company expects to reach an estimated total of 25 new client signings in 2024, representing an approximate 35% growth in client base compared to 2023 NEW YORK, Nov. 21, 2024 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today the signing of four contracts with self-insured employers that are expected to go live in the first quarter of 2025. Dario has added four new employer contracts to the 2025 book of business, continuing the business momentum in the Business-to-Business-to-Consumer (B2B2C) channel and securing recurring revenue from these accounts starting in the first quarter of 2025. The contracts s
Demonstrated strong improvements in financial performance and business momentum.Q3 revenue of $7.42 million increased 18.7% over Q2 2024 and 111% compared to Q3 2023, driven by expansion of B2B2C revenues.Q3 operating loss decreased sequentially by 25.7% to $12 million on a GAAP basis and by 33.3% to $7.1 million on a non-GAAP basis over Q2 2024.Executed synergies from the Dario-Twill merger, expected to reduce operating expenses by approximately 38% by Q1 2025 (compared to Q1 2024) and contributing to an expected 49% reduction in operating losses by Q1 2025 and 59% in non-GAAP operating losses.Significant wins include: 10 B2B2C clients, including a national Medicare advantage health plan, a
The new contract marks the eighth health plan for Dario and will contribute to revenues starting immediately. NEW YORK, Oct. 30, 2024 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today a new contract with a regional health plan in the Medicaid space, which has launched with the full suite of cardiometabolic solutions. The launch with this new health plan marks the third Medicaid client for Dario, continuing a solid momentum within the Medicaid space. The newly signed health plan, familiar with Dario's results with another regional health plan, chose Dario based on the Company's success and reputation for
Concurrently, the Company accepted the resignations of Dr. Colin Goddard and Mr. Joacim Borg OS Therapies (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate biopharmaceutical company, today announced the appointments of Avril McKean Dieser, MA, JD and Olivier R. Jarry, MS, MBA as independent members of the Company's Board of Directors. Collectively, Ms. McKean Dieser and Mr. Jarry bring over 50 years of biopharmaceutical executive decision-making experience to the Company, with a specific focus in commercializing biologic products. "OS Therapies is thrilled to welcome Ms. McKean Dieser and Mr. Jarry to our Board of Directors," sa
Company to host conference call and webcast at 8:30am ET NEW YORK, Oct. 23, 2024 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a global leader in digital health, announced today that it will release its financial results for the 3rd quarter ended September 30th, 2024 and will host a conference call and webcast at 8:30 am Eastern Time, on Thursday, November 7th, 2024, before the market opens. Erez Raphael, Chief Executive Officer, and Steven Nelson, Chief Commercial Officer, will host the call. Conference Call Details Date: Thursday, November 7th, 8:30am ET Dial-in Number: 1-800-717-1738 (domestic) or 1-646-307-1865 (international) Call me™: https://emportal
Integration of behavioral health and wellbeing solutions with navigation and engagement technology creates the most comprehensive solution in the market under the Dario brand NEW YORK, Oct. 17, 2024 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a global leader in digital health, today announces the full integration of Twill's advanced behavioral health and navigation capabilities into the Dario platform. The integration completes Dario's effort to create one of the most comprehensive and effective end-to-end digital health solutions in the market. By unifying data across mental and physical health, Dario offers a more personalized and effective approach to care.
New offer gives Dario access to millions of AARP members, enabling engagement with people over 50 in health and well-being beginning in January 2025 NEW YORK, Oct. 15, 2024 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today a new AARP member benefit that provides members with proven digital behavioral health and well-being solutions from Twill by Dario. The new benefit is expected to launch in January of 2025 for AARP members. For their first digital behavioral health benefit, AARP members have access to Dario's behavioral health platform, Twill by Dario, for an easy way to access the appropriate avenue o
In the news release, National Medicare Health Plan Partners with Twill by Dario to Promote Healthy Aging with New Digital Mental Health Benefits for Seniors, issued Oct. 1, 2024 by DarioHealth Corp. over PR Newswire, we are advised by the company that an edit was made to the second paragraph. The complete, corrected release follows: National Medicare Health Plan Partners with Twill by Dario to Promote Healthy Aging with New Digital Mental Health Benefits for Seniors The new contract significantly expands Dario's footprint with more than a million eligible members beginning January 2025 NEW YORK, Oct. 1, 2024 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a lea
The new contract significantly expands Dario's footprint with more than a million eligible members beginning January 2025 NEW YORK, Oct. 1, 2024 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today a new contract with a national Medicare Advantage health plan (the "Plan") to launch its behavioral health solution for the Plan members beginning in January 2025. This new contract marks the beginning of a strategic relationship, starting with Dario's behavioral health solution, Twill by Dario, in 2025 and potentially expanding to additional Dario solutions in 2026 and beyond. The multi-million-dollar contra
The integration of Twill's condition-specific, expert-led peer groups will enhance the member experience and deepen engagement with Dario's proven cardiometabolic solution NEW YORK, Sept. 12, 2024 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leader in the global digital health market announced today the integration of condition-specific communities and peer groups with personalized navigation capabilities into its cardiometabolic solution to improve outcomes-based engagement, marking a significant milestone in the integration of the Dario-Twill product offering. Social support plays a key role in chronic condition management by improving the psychological we
Dario's leading behavior change solutions continue to win interest in the employer, payer and pharmaceutical markets
DarioHealth (NASDAQ:DRIO) reported quarterly sales of $5.758 million which missed the analyst consensus estimate of $6.758 million by 14.80 percent. This is a 18.51 percent decrease over sales of $7.066 million the same period last year.
Quasi-randomized study demonstrates the value of Dario's integrated approach to provide one solution for members to manage diabetes, pre-diabetes, blood pressure, weight and taking a GLP-1NEW YORK, April 25, 2024 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today new research published in the leading peer-reviewed journal for digital health and medicine, Journal of Internet Medicine (JMIR) demonstrating a clinically significant reduction in blood glucose levels for members using Dario to manage weight alongside diabetes.More than 80% of people living with Type 2 diabetes are overweight and the two conditio
Dario selected to provide integrated and proven solutions to improve employee cardiometabolic healthNEW YORK, April 18, 2024 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today two new contracts to provide integrated chronic condition management solutions for two employers beginning in the second quarter of 2024.The employers, a national supply chain company and a regional education organization, selected Dario's cardiometabolic suite to help improve outcomes for employees with cardiometabolic health conditions, including diabetes, pre-diabetes, hypertension and weight management needs, including support fo
Studies include a Randomized Controlled Trial demonstrating significant reduction in perceived stress for teens
DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today two new contracts to provide integrated chronic condition management solutions for two national employers beginning in the second quarter of 2024.The first employer, a global private investment group, selected Dario's cardiometabolic suite to help improve outcomes for employees with cardiometabolic health conditions, including diabetes, pre-diabetes, hypertension and weight management needs, including support for individuals taking a GLP-1.The second employer, a national professional services company, selected Dario's full suite of solutions to deliver personalized suppor
Stifel analyst David Grossman maintains DarioHealth (NASDAQ:DRIO) with a Buy and maintains $4 price target.
DarioHealth (NASDAQ:DRIO) reported quarterly losses of $(0.41) per share which beat the analyst consensus estimate of $(0.54) by 24.07 percent. This is a 19.61 percent increase over losses of $(0.51) per share from the same period last year.
Alliance Global Partners upgraded DarioHealth from Neutral to Buy and set a new price target of $8.75
Aegis Capital reiterated coverage of DarioHealth with a rating of Buy and set a new price target of $25.00 from $28.00 previously
Aegis Capital reiterated coverage of DarioHealth with a rating of Buy and set a new price target of $28.00 from $35.00 previously
Cowen & Co. initiated coverage of DarioHealth with a rating of Outperform and set a new price target of $31.00
Stifel initiated coverage of DarioHealth with a rating of Buy and set a new price target of $30.00
Cantor Fitzgerald initiated coverage of DarioHealth with a rating of Overweight and set a new price target of $35.00
Aegis Capital reiterated coverage of DarioHealth with a rating of Buy and set a new price target of $35.00 from $25.00 previously
Alliance Global Partners downgraded DarioHealth from Buy to Neutral and set a new price target of $22.25 from $15.60 previously
SC 13G - DarioHealth Corp. (0001533998) (Subject)
SC 13G/A - DarioHealth Corp. (0001533998) (Subject)
SC 13G/A - DarioHealth Corp. (0001533998) (Subject)
SC 13G/A - DarioHealth Corp. (0001533998) (Subject)
SC 13G/A - DarioHealth Corp. (0001533998) (Subject)
SC 13G/A - DarioHealth Corp. (0001533998) (Subject)
SC 13G/A - DarioHealth Corp. (0001533998) (Subject)
SC 13G/A - DarioHealth Corp. (0001533998) (Subject)
SC 13G/A - DarioHealth Corp. (0001533998) (Subject)
SC 13G - DarioHealth Corp. (0001533998) (Subject)